PRAME

QR005, Rb

Artikelnummer:P003-H
Menge:
Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Spezies:Rabbit
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human PRAME
Vorbehandlung:ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Nuclear, membranous
Kontrolle:Testis, melanoma
Synonyme:MAPE, Melanoma antigen preferentially expressed in tumors, OIP 4, OIP-4, OIP4, OPA interacting protein 4, Opa interacting protein OIP4, OPA-interacting protein 4, PRAME, PRAME_HUMAN, Preferentially expressed antigen in melanoma, Preferentially expressed antigen of melanoma, RP23-250F8.3.
Verfügbar in folgenden Ländern:worldwide
Beschreibung

PRAME (Preferentially expressed antigen in melanoma) is a tumor-associated antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. Normal tissues show low or no expression except testis, ovary, placenta, adrenals and endometrium. Therefore, it is called a member of the family of cancer testis antigens. PRAME is also expressed in malignant cells, including leukemias, HodgkinÍs lymphoma and breast cancer. This antibody may be used as melanoma marker to differentiate benign from malign tumors.

Literatur

[1] Ikeda H, LethŽ B, Lehmann F et al. (1997): Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6(2):199-208.
[2] Lezcano C, Jungbluth AA, Nehal KS et al. (2018): PRAME Expression in Melanocytic Tumors. Am J Surg Pathol. 42(11):1456-65.
[3] Nettersheim D, Arndt I, Sharma R (2016): The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas. Br J Cancer. 115(4):454-64.

Kontakt